Inactive Instrument

Highlights CohBar Inc Toronto S.E.

Equities

COBu

US19249J1097

End-of-day quote Toronto S.E. Other stock markets
-	-

Jan. 23	North American Morning Briefing : Stock Futures Steady as Earnings Season Ramps Up	DJ
Jan. 16	North American Morning Briefing : Stock Futures -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : November Rally Pauses Ahead of This Week's PCE Report	Nov. 28	DJ
Morphogenesis, Inc. cancelled the acquisition of CohBar, Inc. in a reverse merger transaction.	Oct. 31	CI
CohBar, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Morphogenesis, Inc. and Cohbar, Inc. Announce Positive Results from Phase 1B Trial of Ifx-Hu2.0, A Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma	23-06-05	CI
Morphogenesis, Inc. entered into a definitive agreement to acquire CohBar, Inc. for approximately $130 million in a reverse merger transaction.	23-05-22	CI
CohBar, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
CohBar, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
CohBar, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
CohBar, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
CohBar, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
CohBar Halves Q4 Net Loss From Year-Ago Levels	22-03-29	MT
CohBar, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-29	CI
CohBar, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-03-29	CI
CohBar, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity	21-08-10	CI
Cohbar, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-10	CI
CohBar, Inc. Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity	21-07-14	CI
Cohbar, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-17	CI
CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity	21-04-21	CI
CohBar : Reports Narrower Q4 Loss	21-03-30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CohBar Inc Toronto S.E.

Equities

COBu

US19249J1097

Highlights

Filters